Lantheus Holdings, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mary Anne Heino
- Full Time Employees
- 808
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 331 Treble Cove Road Bedford MA United States of America 01862
- IPO Date
- Jun 25, 2015
- CIK
- 0001521036
- Website
- lantheus.com
- Similar Companies
- Business
- Lantheus Holdings, Inc. is a global biopharmaceutical company specializing in the development, manufacturing, and commercialization of diagnostic imaging agents and radiopharmaceuticals. The company’s core product portfolio includes radiopharmaceuticals for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging, contrast agents for echocardiography such as DEFINITY® Vial, and generator systems like TechneLite® for technetium-99m production used in nuclear medicine. Lantheus also offers contract development and manufacturing organization (CDMO) services for diagnostic agents and specialty pharmaceuticals, supporting clinical development and commercial manufacturing. Its products primarily serve the oncology, cardiology, and neurology markets, aiding in the diagnosis and management of serious diseases. The company operates globally with headquarters in North Billerica, Massachusetts, and was founded in 1956. In the past two years, Lantheus has undergone significant strategic expansion through acquisitions and product pipeline growth. Notably, it acquired Evergreen Theragnostics in 2025 for $250 million upfront with additional milestone payments, enhancing its radiopharmaceutical capabilities by incorporating scalable manufacturing infrastructure and expanding its oncology diagnostic pipeline with products like OCTEVY™, a PET diagnostic for neuroendocrine tumors. Additionally, Lantheus completed the acquisition of Life Molecular Imaging in mid-2025 for up to $750 million, adding the FDA-approved F-18 PET agent Neuraceq used to detect beta-amyloid plaques in Alzheimer’s disease, a significant complement to its diagnostic portfolio. These acquisitions reinforce Lantheus' strategy to become a fully integrated radiopharmaceutical company encompassing drug development, manufacturing, and commercialization. The company has also announced plans to divest its SPECT business to focus on higher-growth radiopharmaceuticals. Lantheus continues to innovate in molecular imaging with a robust pipeline including new radiotracers targeting cancers and neurological conditions. It supports healthcare providers with clinical education and comprehensive solutions across the diagnostic imaging value chain. In 2025, the company implemented a $400 million stock repurchase program and adjusted its financial guidance reflecting short-term pressures but emphasizing long-term growth through its growing commercial portfolio and clinical assets. Leadership changes during 2025 include executive role shifts to strengthen commercial and operational capabilities. Lantheus is positioning itself as a leader in radiopharmaceutical innovation serving oncology, cardiology, and neurology markets globally.
Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the Year
Lantheus to Present at the William Blair 46th Annual Growth Stock Conference
Lantheus weighs potential $7 billion sale, Bloomberg News reports
Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting
Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
Lantheus Q1 Earnings Call Highlights
These Analysts Raise Their Forecasts On Lantheus After Upbeat Q1 Results
Lantheus Holdings, Inc. (LNTH) Q1 2026 Earnings Call Transcript
Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
Brown Advisory Small Cap Growth Strategy Q1 2026 Portfolio Activity
Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Lantheus Holdings: Tensions From The PDUFA Extension
Lantheus (NASDAQ:LNTH) & High Tide (NASDAQ:HITI) Financial Contrast
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
Why Lantheus Holdings Stock Popped by Almost 12% Last Month
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
Elo Mutual Pension Insurance Co Acquires New Stake in Lantheus Holdings, Inc. $LNTH
Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH
Lantheus Holdings, Inc. (LNTH) Q4 2025 Earnings Call Transcript